论文部分内容阅读
目的 探讨预防浅表性膀胱癌经尿道膀胱肿瘤电切术 (TUR Bt)术后复发的新方法。方法 初发浅表性膀胱肿瘤TUR Bt术后膀胱黏膜下注射抗肿瘤药物 (比柔吡星 )患者 6 8例 (注射组 ) ,其中肿瘤单发 4 4例、多发 2 4例 ;以TUR Bt术后膀胱内灌注化疗药物的 74例患者作为对照 (灌注组 ) ,其中肿瘤单发 4 9例、多发 2 5例。根据随访结果对两种方法预防肿瘤复发的疗效进行评价。结果 注射组平均随访 38个月 ,对照组平均随访 35个月。注射组随访期内有 8例复发 (11 8% ) ,灌注组随访期内有 2 2例复发 (2 9 7% ) ,两组复发率相比 ,差异有非常显著意义 (χ2 =0 0 13,P <0 0 1) ;注射组和灌注组中 ,肿瘤单发与多发之间复发率相比 ,差异无显著意义 (χ2 =0 719,P >0 0 5 )。结论浅表性膀胱癌TUR Bt术后单次黏膜下注射抗肿瘤药物 ,操作简单、安全有效、副作用少、费用低 ,是治疗膀胱浅表肿瘤的一种实用方法 ,可有效地预防膀胱肿瘤术后复发。
Objective To explore a new method to prevent the recurrence of superficial bladder cancer after transurethral resection of bladder tumor (TUR Bt). Methods Sixty-eight patients (48 cases) with TUR Bt submucosal instillation of bladder tumor were included in this study. Among them, 44 cases were single and 24 cases were multiple. TUR Bt Totally 74 patients with intravesical chemotherapy were selected as controls (perfusion group), of which 49 were single and 25 were multiple. According to the follow-up results of the two methods to evaluate the efficacy of tumor recurrence. Results The patients in the injection group were followed up for an average of 38 months. The patients in the control group were followed up for an average of 35 months. There were 8 recurrent cases (118%) in the injection group and 22 cases (297%) in the perfusion group during the follow-up period. There was significant difference between the two groups in recurrence rate (χ2 = 0 0 13 , P <0.01). There was no significant difference in relapse rate between single and multiple tumors in the injected group and the perfusion group (χ 2 = 0 719, P 0 05). Conclusion TUR Bt superficial bladder cancer after a single submucosal injection of anti-tumor drugs, simple, safe and effective, less side effects, low cost, is a practical method of treatment of superficial bladder tumors, which can effectively prevent bladder cancer surgery After the recurrence.